Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 0.28p
   
  • Change Today:
      0.000p
  • 52 Week High: 1.22p
  • 52 Week Low: 0.20p
  • Currency: UK Pounds
  • Shares Issued: 2,148.96m
  • Volume: 212,860
  • Market Cap: £5.91m

Deal with Barclays    Trade now with Barclays Stockbrokers

Latest ShareCast News

TheraCryf signs deal for Ox-1 addiction treatment development

By Josh White

Date: Monday 12 May 2025

(Sharecast News) - TheraCryf announced on Monday that it has entered into a master service agreement with contract research organisation Pharmaron UK to support the development of its Orexin-1 addiction treatment programme.

Evgen upbeat on start of glioblastoma research project

By Josh White

Date: Thursday 26 Oct 2023

(Sharecast News) - Clinical-stage drug developer Evgen Pharma announced on Thursday that it has partnered with Dr Marjolein Geurts, a neuro-oncologist at Erasmus University Medical Centre, to start a ground-breaking research initiative in glioblastoma.

Evgen Pharma doses first volunteers in SFX-01 trial

By Josh White

Date: Wednesday 16 Nov 2022

(Sharecast News) - Clinical-stage drug developer Evgen Pharma has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating, randomised phase 1 and 1b clinical trial, it announced on Wednesday.

Evgen starts recruiting volunteers for trial of ... 12-Oct-2022 ShareCast
Evgen agrees fresh licensing deal with Spanish i... 18-Jan-2022 ShareCast
Evgen pleased with preclinical data on SFX-01 13-Jul-2021 ShareCast
Evgen 'surprised and disappointed' by findings i... 09-Jul-2021 ShareCast
Evgen upbeat on new data on potential breast can... 14-Jun-2021 ShareCast
Evgen appoints Helen Kuhlman as chief business o... 22-Mar-2021 ShareCast
Evgen Covid-19 trial given all-clear on safety a... 11-Mar-2021 ShareCast
Evgen makes progress with recruitment in 'STAR' ... 17-Feb-2021 ShareCast
Evgen announces positive preclinical data for SF... 22-Jan-2021 ShareCast
Evgen reports 'highly positive' data from SFX-01... 21-Jan-2021 ShareCast
Evgen Pharma makes progress with 'STAR' trial re... 19-Jan-2021 ShareCast
Evgen Pharma performs in line with forecasts in ... 10-Dec-2020 ShareCast
Evgen doses first patients in 'STAR' respiratory... 23-Nov-2020 ShareCast
Evgen gets full approval for SFX-01 trial in Cov... 23-Oct-2020 ShareCast
Evgen Pharma licences technology to Juvenescence 15-Sep-2020 ShareCast
Evgen's 'SFX-01' to be tested with Covid-19 pati... 17-Jun-2020 ShareCast
Losses widen as Evgen Pharma develops SFX-01 15-Jun-2020 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.28p
Change Today 0.000p
% Change 0.00 %
52 Week High 1.22p
52 Week Low 0.20p
Volume 212,860
Shares Issued 2,148.96m
Market Cap £5.91m

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
46.02% below the market average46.02% below the market average46.02% below the market average46.02% below the market average46.02% below the market average
52.17% above the sector average52.17% above the sector average52.17% above the sector average52.17% above the sector average52.17% above the sector average
Price Trend
92.83% below the market average92.83% below the market average92.83% below the market average92.83% below the market average92.83% below the market average
82.61% below the sector average82.61% below the sector average82.61% below the sector average82.61% below the sector average82.61% below the sector average
Income Not Available
Growth
15.76% below the market average15.76% below the market average15.76% below the market average15.76% below the market average15.76% below the market average
26.67% below the sector average26.67% below the sector average26.67% below the sector average26.67% below the sector average26.67% below the sector average

Theracryf Dividends

No dividends found

Trades for 02-Jun-2025

Time Volume / Share Price
08:29 212,860 @ 0.25p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page